ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Others proposed that over-expression of the efflux drug transporter P-glycoprotein (Pgp) partially contributed to imatinib resistance in imatinib-resistant K562 CML cells having no BCR-ABL mutations [32].